Retrotope announces opening of second clinical trial site for enrollment in Friedreich’s ataxia clinical trial.

Retrotope announces the opening of second clinical trial site, the Collaborative Neuroscience Network, LLC. ("CNS") in Long Beach, California, for the ongoing 28-day, first-in-human randomized, double-blind, controlled, ascending dose study of orally dosed RT001 to evaluate the safety, tolerability, pharmacokinetics (PK), disease state, and exploratory endpoints in patients with Friedreich's ataxia (FA). This site is a specialized facility that is experienced with running Phase 1 studies for neurological diseases. We need about 10 additional subjects to enroll in this study and hope that a site in California aids in subject participation.

Read the entire article HERE